Drug Pipeline

BMS-986393 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
1
Phase 3
1
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06615479 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in… Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting
Phase 2
NCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in… Multiple Myeloma Recruiting
Phase 1
NCT06121843 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene… Multiple Myeloma Recruiting
Sponsors Running BMS-986393 Trials
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (3)
Disease Areas
Multiple Myeloma (3)
Get alerts when BMS-986393 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free